Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday

Posted by Brenda Bartman on May 5th, 2026

Belite Bio (NASDAQ:BLTE – Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.18. On average, analysts expect Belite Bio to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Belite Bio Stock Up 2.5%

Shares of BLTE traded up $3.88 during midday trading on Tuesday, reaching $158.39. 19,351 shares of the stock were exchanged, compared to its average volume of 185,602. Belite Bio has a 12-month low of $56.10 and a 12-month high of $200.00. The firm has a 50 day simple moving average of $167.98 and a 200-day simple moving average of $151.52. The company has a market cap of $6.33 billion, a price-to-earnings ratio of -68.86 and a beta of -1.19.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BLTE shares. Wall Street Zen raised Belite Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Cantor Fitzgerald raised their price target on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a research note on Tuesday, April 7th. Mizuho set a $223.00 price objective on Belite Bio in a research note on Thursday, February 19th. Finally, Needham & Company LLC set a $217.00 price objective on Belite Bio in a research note on Tuesday, March 3rd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Belite Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.33.

Get Our Latest Stock Report on BLTE

Insider Buying and Selling

In related news, CFO Hao-Yuan Chuang sold 6,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $181.50, for a total value of $1,125,300.00. Following the transaction, the chief financial officer directly owned 93,800 shares of the company’s stock, valued at approximately $17,024,700. This trade represents a 6.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wan-Shan Chen sold 1,100 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $180.43, for a total value of $198,473.00. Following the completion of the transaction, the director directly owned 9,096 shares in the company, valued at $1,641,191.28. The trade was a 10.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,500 shares of company stock valued at $4,290,813 over the last 90 days. 13.29% of the stock is currently owned by insiders.

Institutional Trading of Belite Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its holdings in Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after buying an additional 282 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Belite Bio in the 4th quarter valued at approximately $108,000. Bank of America Corp DE grew its holdings in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after buying an additional 257 shares during the last quarter. Brooklyn Investment Group acquired a new stake in Belite Bio in the 4th quarter valued at approximately $287,000. Finally, Royal Bank of Canada acquired a new stake in Belite Bio in the 4th quarter valued at approximately $334,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

About Belite Bio

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.